Category Archives: Global News Feed

500,000+ square foot facility to support commercial-scale biomanufacturing

See the article here:
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, 2022 in Lisbon, Portugal.

Excerpt from:
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

POTOMAC, Md., April 18, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (OTC: ONOV) announces the closing of its acquisition of Lexington Solutions Group (“LSG”), a $4 million government contractor focused on information operations.

Original post:
Castellum, Inc. Closes on the Acquisition of Lexington Solutions Group

Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022

Continued here:
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Designation that has the goal of delaying chronic kidney disease (CKD), preventing end-stage renal disease (ESRD), and preventing the need for dialysis. Social Capital Suvretta Holdings Corp. III (SCS) (Nasdaq: DNAC), is a special purpose acquisition company. ProKidney and SCS today announced that they will host an analyst and investor day in New York on Thursday, April 28, 2022, beginning at 8:00 a.m. ET.

Read the original:
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases.   The article titled, "Antibody Response to SARS-CoV-2 mRNA Vaccines in Patients with Rheumatic Diseases in Japan: Interim Analysis of a Multicenter Cohort Study", is published in Modern Rheumatology and can be found here.

Link:
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Distinguished neurosurgeon-inventor to lead continued development of Accelus’s Remi™ Robotic Navigation System Distinguished neurosurgeon-inventor to lead continued development of Accelus’s Remi™ Robotic Navigation System

Read more:
Accelus Appoints Kevin Foley, MD as Chief Robotics Officer

BIGS premium flower line and Hash-Wrapped Smoke are latest offerings from California’s No. 1 selling cannabis brand per Headset

Original post:
Lowell Herb Co. Expands Award-Winning Cannabis Brand with All-New Products

Automated benchtop BioXp™ system offers significant quality, time, and cost advantages for DNA and mRNA synthesis compared to alternative options Automated benchtop BioXp™ system offers significant quality, time, and cost advantages for DNA and mRNA synthesis compared to alternative options

More:
Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington...

DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31

Go here to read the rest:
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments